Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases
Advanced glycation end products (AGEs) have been implicated in vision loss associated with macula degeneration, cataract formation, diabetic retinopathy and glaucoma. This pathogenic potential is mainly attributed to their accumulation in ocular tissues where they mediate aberrant crosslinking of ex...
Gespeichert in:
| Veröffentlicht in: | Progress in retinal and eye research 2014-09, Vol.42, p.85-102 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | |
| container_start_page | 85 |
| container_title | Progress in retinal and eye research |
| container_volume | 42 |
| creator | Kandarakis, Stylianos A. Piperi, Christina Topouzis, Fotis Papavassiliou, Athanasios G. |
| description | Advanced glycation end products (AGEs) have been implicated in vision loss associated with macula degeneration, cataract formation, diabetic retinopathy and glaucoma.
This pathogenic potential is mainly attributed to their accumulation in ocular tissues where they mediate aberrant crosslinking of extracellular matrix proteins and disruption of endothelial junctional complexes that affects cell permeability, mediates angiogenesis and breakdown of the inner blood-retinal barrier. Furthermore, AGEs severely affect cellular metabolism by disrupting ATP production, enhancing oxidative stress and modulating gene expression of anti-angiogenic and anti-inflammatory genes. Elucidation of AGE-induced mechanisms of action in different eye compartments will help in the understanding of the complex cellular and molecular processes associated with eye diseases. Several pharmaceutical agents with anti-glycating and anti-oxidant properties as well as AGE crosslink ‘breakers’ have been currently applied to eye diseases. The role of diet and the beneficial effects of certain nutriceuticals provide an alternative way to manage chronic visual disorders that affect the quality of life of millions of people. |
| doi_str_mv | 10.1016/j.preteyeres.2014.05.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566819692</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1350946214000287</els_id><sourcerecordid>1566819692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-67714ef6ad9f59c594fb46c21e18e4b285dc72f9ed6e78df1553b04a774761e63</originalsourceid><addsrcrecordid>eNqFkD9PwzAQxS0EglL4CshjGRLsxH_iEVApSJVYYGKwHPvSukrjYqdI_fakaoGR6W547967H0KYkpwSKu5W-SZCDzuIkPKCUJYTnhNSnKARrWSZUVHy02EvOckUE8UFukxpRQgRRPFzdFEwRXjF1Qh9TNcQF75b4BhawKHBxn2ZzoLDi3ZnTe9Dl0Hn8CYGt7V9wpP72TTdYt_hfgl4Y_plqH1ow2K3dw-dsPMJTIJ0hc4a0ya4Ps4xen-avj0-Z_PX2cvj_TyzTJZ9JqSkDBphnGq4slyxpmbCFhRoBawuKu6sLBoFToCsXEM5L2vCjJRMCgqiHKPJ4e7Q8XMLqddrnyy0rekgbJOmXIiKKqGKQVodpDaGlCI0ehP92sSdpkTv0eqV_kOr92g14XpAO1hvjinbeg3u1_jDchA8HAQw_PrlIepkPexR-gi21y74_1O-AQr3j-E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1566819692</pqid></control><display><type>article</type><title>Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kandarakis, Stylianos A. ; Piperi, Christina ; Topouzis, Fotis ; Papavassiliou, Athanasios G.</creator><creatorcontrib>Kandarakis, Stylianos A. ; Piperi, Christina ; Topouzis, Fotis ; Papavassiliou, Athanasios G.</creatorcontrib><description>Advanced glycation end products (AGEs) have been implicated in vision loss associated with macula degeneration, cataract formation, diabetic retinopathy and glaucoma.
This pathogenic potential is mainly attributed to their accumulation in ocular tissues where they mediate aberrant crosslinking of extracellular matrix proteins and disruption of endothelial junctional complexes that affects cell permeability, mediates angiogenesis and breakdown of the inner blood-retinal barrier. Furthermore, AGEs severely affect cellular metabolism by disrupting ATP production, enhancing oxidative stress and modulating gene expression of anti-angiogenic and anti-inflammatory genes. Elucidation of AGE-induced mechanisms of action in different eye compartments will help in the understanding of the complex cellular and molecular processes associated with eye diseases. Several pharmaceutical agents with anti-glycating and anti-oxidant properties as well as AGE crosslink ‘breakers’ have been currently applied to eye diseases. The role of diet and the beneficial effects of certain nutriceuticals provide an alternative way to manage chronic visual disorders that affect the quality of life of millions of people.</description><identifier>ISSN: 1350-9462</identifier><identifier>EISSN: 1873-1635</identifier><identifier>DOI: 10.1016/j.preteyeres.2014.05.002</identifier><identifier>PMID: 24905859</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>AGEs ; Angiogenesis ; Anti-glycating agents ; Blood-retinal barrier ; Blood-Retinal Barrier - physiopathology ; Eye disease ; Eye Diseases - physiopathology ; Glycation End Products, Advanced - physiology ; Humans ; Inflammation ; Neovascularization, Pathologic - physiopathology ; Oxidative Stress - physiology</subject><ispartof>Progress in retinal and eye research, 2014-09, Vol.42, p.85-102</ispartof><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-67714ef6ad9f59c594fb46c21e18e4b285dc72f9ed6e78df1553b04a774761e63</citedby><cites>FETCH-LOGICAL-c473t-67714ef6ad9f59c594fb46c21e18e4b285dc72f9ed6e78df1553b04a774761e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1350946214000287$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24905859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kandarakis, Stylianos A.</creatorcontrib><creatorcontrib>Piperi, Christina</creatorcontrib><creatorcontrib>Topouzis, Fotis</creatorcontrib><creatorcontrib>Papavassiliou, Athanasios G.</creatorcontrib><title>Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases</title><title>Progress in retinal and eye research</title><addtitle>Prog Retin Eye Res</addtitle><description>Advanced glycation end products (AGEs) have been implicated in vision loss associated with macula degeneration, cataract formation, diabetic retinopathy and glaucoma.
This pathogenic potential is mainly attributed to their accumulation in ocular tissues where they mediate aberrant crosslinking of extracellular matrix proteins and disruption of endothelial junctional complexes that affects cell permeability, mediates angiogenesis and breakdown of the inner blood-retinal barrier. Furthermore, AGEs severely affect cellular metabolism by disrupting ATP production, enhancing oxidative stress and modulating gene expression of anti-angiogenic and anti-inflammatory genes. Elucidation of AGE-induced mechanisms of action in different eye compartments will help in the understanding of the complex cellular and molecular processes associated with eye diseases. Several pharmaceutical agents with anti-glycating and anti-oxidant properties as well as AGE crosslink ‘breakers’ have been currently applied to eye diseases. The role of diet and the beneficial effects of certain nutriceuticals provide an alternative way to manage chronic visual disorders that affect the quality of life of millions of people.</description><subject>AGEs</subject><subject>Angiogenesis</subject><subject>Anti-glycating agents</subject><subject>Blood-retinal barrier</subject><subject>Blood-Retinal Barrier - physiopathology</subject><subject>Eye disease</subject><subject>Eye Diseases - physiopathology</subject><subject>Glycation End Products, Advanced - physiology</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Neovascularization, Pathologic - physiopathology</subject><subject>Oxidative Stress - physiology</subject><issn>1350-9462</issn><issn>1873-1635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD9PwzAQxS0EglL4CshjGRLsxH_iEVApSJVYYGKwHPvSukrjYqdI_fakaoGR6W547967H0KYkpwSKu5W-SZCDzuIkPKCUJYTnhNSnKARrWSZUVHy02EvOckUE8UFukxpRQgRRPFzdFEwRXjF1Qh9TNcQF75b4BhawKHBxn2ZzoLDi3ZnTe9Dl0Hn8CYGt7V9wpP72TTdYt_hfgl4Y_plqH1ow2K3dw-dsPMJTIJ0hc4a0ya4Ps4xen-avj0-Z_PX2cvj_TyzTJZ9JqSkDBphnGq4slyxpmbCFhRoBawuKu6sLBoFToCsXEM5L2vCjJRMCgqiHKPJ4e7Q8XMLqddrnyy0rekgbJOmXIiKKqGKQVodpDaGlCI0ehP92sSdpkTv0eqV_kOr92g14XpAO1hvjinbeg3u1_jDchA8HAQw_PrlIepkPexR-gi21y74_1O-AQr3j-E</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Kandarakis, Stylianos A.</creator><creator>Piperi, Christina</creator><creator>Topouzis, Fotis</creator><creator>Papavassiliou, Athanasios G.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases</title><author>Kandarakis, Stylianos A. ; Piperi, Christina ; Topouzis, Fotis ; Papavassiliou, Athanasios G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-67714ef6ad9f59c594fb46c21e18e4b285dc72f9ed6e78df1553b04a774761e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>AGEs</topic><topic>Angiogenesis</topic><topic>Anti-glycating agents</topic><topic>Blood-retinal barrier</topic><topic>Blood-Retinal Barrier - physiopathology</topic><topic>Eye disease</topic><topic>Eye Diseases - physiopathology</topic><topic>Glycation End Products, Advanced - physiology</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Neovascularization, Pathologic - physiopathology</topic><topic>Oxidative Stress - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kandarakis, Stylianos A.</creatorcontrib><creatorcontrib>Piperi, Christina</creatorcontrib><creatorcontrib>Topouzis, Fotis</creatorcontrib><creatorcontrib>Papavassiliou, Athanasios G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in retinal and eye research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kandarakis, Stylianos A.</au><au>Piperi, Christina</au><au>Topouzis, Fotis</au><au>Papavassiliou, Athanasios G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases</atitle><jtitle>Progress in retinal and eye research</jtitle><addtitle>Prog Retin Eye Res</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>42</volume><spage>85</spage><epage>102</epage><pages>85-102</pages><issn>1350-9462</issn><eissn>1873-1635</eissn><abstract>Advanced glycation end products (AGEs) have been implicated in vision loss associated with macula degeneration, cataract formation, diabetic retinopathy and glaucoma.
This pathogenic potential is mainly attributed to their accumulation in ocular tissues where they mediate aberrant crosslinking of extracellular matrix proteins and disruption of endothelial junctional complexes that affects cell permeability, mediates angiogenesis and breakdown of the inner blood-retinal barrier. Furthermore, AGEs severely affect cellular metabolism by disrupting ATP production, enhancing oxidative stress and modulating gene expression of anti-angiogenic and anti-inflammatory genes. Elucidation of AGE-induced mechanisms of action in different eye compartments will help in the understanding of the complex cellular and molecular processes associated with eye diseases. Several pharmaceutical agents with anti-glycating and anti-oxidant properties as well as AGE crosslink ‘breakers’ have been currently applied to eye diseases. The role of diet and the beneficial effects of certain nutriceuticals provide an alternative way to manage chronic visual disorders that affect the quality of life of millions of people.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24905859</pmid><doi>10.1016/j.preteyeres.2014.05.002</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1350-9462 |
| ispartof | Progress in retinal and eye research, 2014-09, Vol.42, p.85-102 |
| issn | 1350-9462 1873-1635 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1566819692 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | AGEs Angiogenesis Anti-glycating agents Blood-retinal barrier Blood-Retinal Barrier - physiopathology Eye disease Eye Diseases - physiopathology Glycation End Products, Advanced - physiology Humans Inflammation Neovascularization, Pathologic - physiopathology Oxidative Stress - physiology |
| title | Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A05%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20role%20of%20advanced%20glycation-end%20products%20(AGEs)%20in%20the%20pathobiology%20of%20eye%20diseases&rft.jtitle=Progress%20in%20retinal%20and%20eye%20research&rft.au=Kandarakis,%20Stylianos%20A.&rft.date=2014-09-01&rft.volume=42&rft.spage=85&rft.epage=102&rft.pages=85-102&rft.issn=1350-9462&rft.eissn=1873-1635&rft_id=info:doi/10.1016/j.preteyeres.2014.05.002&rft_dat=%3Cproquest_cross%3E1566819692%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1566819692&rft_id=info:pmid/24905859&rft_els_id=S1350946214000287&rfr_iscdi=true |